SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following news of a $400 million AI partnership with Perplexity, combined with a $500 million stock buyback program and positive Q3 earnings results. The community is discussing whether this marks a true turnaround for the stock, with some anticipating a short squeeze while others remain skeptical of the company's long-term profitability.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending downwards, with community members expressing concerns about recent performance despite a reported earnings beat. Discussions center around a distributor termination charge impacting EPS, as well as potential channel stuffing and inventory issues. Some investors view the dip as a buying opportunity, citing long-term growth potential and Pepsi's increased involvement, while others are losing faith.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its multi-year partnership with ESPN, making it the official sportsbook and odds provider. While some see this as a major catalyst for growth, others question its immediate impact given competition from prediction markets and potential earnings headwinds. Community discussions revolve around the deal's potential to boost market share and brand visibility versus concerns about management and overall market conditions.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix's stock is trending downwards as investors express frustration and distrust in management following repeated delays and missed deadlines, specifically regarding commercial smartphone production. The community is actively discussing the company's 2026 outlook, potential acquisitions, and the likelihood of securing purchase orders, with some expressing concern that competitors may catch up due to the delays, while others await CES for updates on smart eyewear products.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to investor frustration after earnings, with the community expressing disappointment over a lack of new partnerships and concerns about the CEO's strategy, especially regarding the CIC/Flu program. Many feel the company isn't prioritizing shareholder value, while others suggest a potential acquisition could be the best path forward amid skepticism about current management and execution.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending following a significant stock drop, despite positive earnings results and raised revenue guidance, sparking discussions about an overreaction. Community members are debating whether the dip presents a buying opportunity or if concerns about future growth and competition from AI are warranted, while analysts are weighing in with mixed opinions and price target adjustments.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors digest its latest earnings report, with some analysts raising price targets. Despite the positive outlook, the stock is experiencing volatility as the community debates whether the current valuation is justified and anticipates potential upgrades. Discussions also include the impact of prediction markets and potential partnerships.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending downwards as investors react negatively to news of a potential $250M ATM equity offering, sparking concerns about dilution and private equity influence. The stock's underperformance is fueling frustration, with community members citing management's perceived disregard for share price and questionable capital allocation. Despite revenue growth and long-term potential in the space sector, the market is expressing doubt in Redwire's execution and leadership.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending after a recent forecast disappointed some investors, leading to discussions about reduced full-year guidance and profitability. Despite the negative sentiment, some traders see this as a buying opportunity, referencing the stock's history of rebounding after similar drops. The community is actively debating the company's valuation, growth prospects, and the potential impact of tariffs.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending amid discussions about its recent performance and future potential, with some investors expressing disappointment over a recent sell-off despite strong revenue growth, while others see it as a buying opportunity. Community members are focused on the potential of RECORLEV to drive significant revenue and profitability in the coming years. Discussions also include speculation about potential buyout offers and the company's overall long-term prospects in the biopharmaceutical space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of +36.00% and +55.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of +12.96% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews

Latest Ratings for TCRX
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021Cowen & Co.Initiates Coverage OnOutperform Aug 2021Morgan StanleyInitiates Coverage...

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts

TScan Therapeutics (TCRX) Gets a Buy from Wedbush

In a report released today, David Nierengarten from Wedbush assigned a Buy rating to TScan Therapeutics (TCRX Research Report), with a price targ...

Buy Rating Affirmed for TScan Therapeutics Amidst Strong Pipeline Progress and Robust Financial Health

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on TScan Therapeutics (TCRX Research Report), with a pri...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Current Price	$1.12
Prev Close	$1.14
Open	$1.11
Dividend Yield	0.00%
50-Day Moving Average	$1.94
Beta	1.10
Avg. Volume	763,452.00
PE Ratio	-1.04

52-Week High	$6.23
52-Week Low	$1.02
Market Capitalization	$64.41M
EPS (Annual)	-$1.14
Price to Book	0.36
Revenue Per Employee	$14,515.46
Enterprise Value/EBITDA	N/A

TCRX
Tscan Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCRX News

TCRXTscan Therapeutics Inc